^
    15h
    KEVLARx: RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer (clinicaltrials.gov)
    P2, N=216, Active, not recruiting, EpicentRx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Jul 2025 --> Jul 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    cisplatin • nibrozetone (RRx-001)
    4d
    Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Cancer. (PubMed, Curr Cancer Drug Targets)
    HHT has been identified as an impediment to cell invasion and metastasis in PC via the EphB4/SRI/EMT axis. Additionally, HHT enhances the efficacy of ERT in inhibiting the migration of PC cells.
    Journal
    |
    CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • EPHB4 (EPH receptor B4) • SRI (Sorcin, 22 KDa Protein)
    |
    erlotinib • Synribo (omacetaxine mepesuccinate)
    10d
    Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    10d
    Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)
    P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University
    New P2/3 trial
    |
    azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin
    15d
    Activation of c-Myc confers resistance to venetoclax via inhibition of Bim in t(8;21)-positive acute myeloid leukemia. (PubMed, Cell Commun Signal)
    c-Myc activation is a key driver of VEN resistance in t(8;21) AML. HHT acts as a mechanistically complementary agent, restoring VEN sensitivity. These results provide a preclinical rationale for clinical evaluation of VEN-HHT combination therapy in genetically defined AML subsets.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2L11 (BCL2 Like 11)
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    15d
    Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • Synribo (omacetaxine mepesuccinate)
    25d
    CD71-Targeted and ROS-Responsive Micelles for Homoharringtonine Delivery to Enhance Therapeutic Efficiency Against FLT3-ITD Acute Myeloid Leukemia. (PubMed, Int J Nanomedicine)
    Therefore, this platform is particularly suited for the treatment of FLT3-ITD AML while potentially applicable to other AML subtypes with high CD71 expression. By enabling specific intracellular accumulation of HHT and multitarget inhibition of FLT3 signaling pathways, this system achieves enhanced anti-AML efficacy both in vitro and in vivo, offering strong potential for future clinical translation.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • TFRC
    |
    Synribo (omacetaxine mepesuccinate)
    29d
    CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization. (PubMed, Mater Today Bio)
    The resulting nanoparticles were investigated in a refractory AML mouse model (AML1-ETO & C-KITD816V) with a high level of CXCR4 and in the t(8; 21)-positive AML cell line Kasumi-1. It was shown that E5-LNP@siAE effectively achieved RNAi of AML1-ETO and antagonism of CXCR4, thereby synergistically inducing effective multi-lineage differentiation, leading to significantly enhanced differentiation-post apoptotic responses of AML cells to homoharringtonine and remarkably prolonged survival in refractory AML mice.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
    |
    Synribo (omacetaxine mepesuccinate)
    1m
    Bortezomib synergizes with homoharringtonine in FLT3-ITD-relapsed/refractory acute myeloid leukemia by inducing FLT3-ITD protein degradation. (PubMed, Clin Exp Med)
    We previously conducted a prospective clinical trial on R/R AML with chemotherapy regimen BHA (bortezomib, homoharringtonine and cytarabine), which demonstrated promising efficacy in patients with FLT3-mutated R/R AML. Notably, this degradation effect was partially reversed by chloroquine. These findings demonstrate that bortezomib and homoharringtonine have synergistic effects and lead to degradation of FLT3-ITD oncoprotein, potentially contributing to a higher complete remission rate in FLT3-ITD R/R AML.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    cytarabine • bortezomib • Synribo (omacetaxine mepesuccinate) • chloroquine phosphate
    1m
    HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting | N=60 --> 41 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Dec 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • Synribo (omacetaxine mepesuccinate)
    2ms
    Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH wild-type
    |
    LMP744